On August 12, 2019 PharmaMar (MSE:PHM) reported that the International Association for the Study of Lung Cancer (IASLC) has published the list of abstracts titles to be presented during the congress that will take place from September 7th to 10th in Barcelona (Press release, PharmaMar, AUG 12, 2019, View Source [SID1234538599]). Three abstracts will be presented on lurbinectedin for the treatment of small cell lung cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Targeting Transcription (Including Lurbinectedin)
Mini Symposium Oral Session: "Molecular Subsets and Novel Targeted Approaches to Small Cell and Neuroendocrine Cancers," on September 10th, 2019, from 12:00 to 12:15 in the Colorado Springs Room
Presenter: Dr. Camilla L. Christensen, Harvard University
Antitumor Activity of Single Agent Lurbinectedin in Patients with Relapsed SCLC Occurring ≥30 Days After Last Platinum Dose. (Abstract 1710).
Poster: September 8th, 2019, from 8:00 to 18:00 in the Exhibit Hall
Session: P1.12 – Small Cell Lung Cancer/NET
Lead author: José Manuel Trigo, Hospital Universitario Virgen de la Victoria.
Lurbinectedin (L) Combined with Paclitaxel (P) or Irinotecan (I) in Relapsed SCLC. Results from Two Phase Ib Trials. (Abstract 1588).
Poster: September 9th, 2019, from 8:00 to 18:00 in the Exhibit Hall
Session: P2.12 – Small Cell Lung Cancer/NET
Lead author: Santiago Ponce, Hospital Universitario 12 de Octubre.
Legal warning
This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.